anti-cancer drugs – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:19:00 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg anti-cancer drugs – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Octreotide Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-octreotide-market-2021-2025/ Mon, 19 Jul 2021 02:43:41 +0000 https://www.cri-report.com/?post_type=product&p=13247 In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Octreotide in the Chinese market decreased to CNY690 million, a year-on-year decrease of 3.8%.

The post Investigation Report on China’s Octreotide Market 2021-2025 first appeared on CRI Report.

]]> Octreotide is a derivative of artificially modified natural somatostatin, which is an octapeptide. Its physiological effects include inhibiting growth hormone function, inhibiting the secretion of gastric acid, pancreatic enzymes, glucagon and insulin, reducing visceral blood flow, reducing gastrointestinal motility, etc. It is clinically used for emergency treatment of esophageal-varices bleeding, treatment of acromegaly and treatment related to gastrointestinal endocrine tumors. Its product SANDOSTATIN was developed by Novartis Pharma Schweiz AG and was approved to enter the Chinese market in 2003. Since then, some generic drugs have also been listed in the Chinese market. By 2020, there are several manufacturers in the Chinese Octreotide market, among which Novartis Pharma Schweiz AG accounts for the most market share.

According to CRI’s market research, the sales value of Octreotide in the Chinese market from 2016 to 2019 were relatively stable. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Octreotide in the Chinese market decreased to CNY690 million, a year-on-year decrease of 3.8%. From 2016 to 2020, the CAGR of Octreotide sales value in the Chinese market is -0.48%.

CRI expects that with the relief of COVID-19, the sales value of Octreotide in the Chinese market will have a restorative growth from 2021 to 2025. In addition, compared with similar drugs, Octreotide has a longer action time, not only can extensively inhibit the secretion of digestive juice, but also promotes the absorption of digestive juice by the intestinal mucosa. Based on these advantages, the sales value and sales volume of Octreotide still has room to rise. At the same time, in recent years, the pace of life of Chinese residents has accelerated, and irregular eating habits have increased the prevalence of various gastrointestinal diseases. Therefore, the demand for Octreotide will continue to expand and its sales value will continue to grow from 2021 to 2025.

Topics Covered:

  • -The impact of COVID-19 on China’s Octreotide market
  • – Sales value of China’s Octreotide 2016-2020
  • – Competitive landscape of China’s Octreotide market
  • – Prices of Octreotide in China
  • – Prices of Octreotide in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Octreotide market
  • – Prospect of China’s Octreotide market from 2021 to 2025

The post Investigation Report on China’s Octreotide Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Temozolomide Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-temozolomide-market-2021-2025/ Mon, 19 Jul 2021 02:43:42 +0000 https://www.cri-report.com/?post_type=product&p=13252 Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Temozolomide in the Chinese market decreased to CNY793 million in 2020 and the CAGR of Temozolomide in sales value from 2016 to 2020 is 9.04%.

The post Investigation Report on China’s Temozolomide Market 2021-2025 first appeared on CRI Report.

]]> Temozolomide is a second-generation alkylating agent. It is an oral chemotherapeutic drug used to treat brain cancers such as adult malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc. The drug was approved to enter the Chinese market under the trade name TEMODAL in 2007. By 2020, Temozolomide has been included in China’s Class B medical insurance. There are many manufacturers in the Chinese market in 2020, among which Merck Sharp & Dohme Ltd is the main manufacturer.

According to CRI’s market research, the sales value of Temozolomide in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Temozolomide in the Chinese market decreased to CNY793 million in 2020 and the CAGR of Temozolomide in sales value from 2016 to 2020 is 9.04%.

CRI expects that with the relief of COVID-19, the sales value of Temozolomide in the Chinese market will have a restorative growth from 2021 to 2025. In addition, as the incidence of primary brain cancer increases, other cancers can cause secondary brain cancer. Therefore, with the widespread use of digital electronic products and the increase in the incidence of other cancers, the incidence of brain cancer is also increasing year by year, the sales value and sales volume of Temozolomide for the treatment of brain cancer will continue to increase. At the same time, Temozolomide has the characteristics of easily penetrating the blood-cerebrospinal fluid barrier and mild adverse reactions. CRI predicts that the sales value and sales volume of Temozolomide in the Chinese market will have room for increase from 2021 to 2025.

 

Topics Covered:

  • -The impact of COVID-19 on China’s Temozolomide market
  • – Sales value of China’s Temozolomide 2016-2020
  • – Competitive landscape of China’s Temozolomide market
  • – Prices of Temozolomide in China
  • – Prices of Temozolomide in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Temozolomide market
  • – Prospect of China’s Temozolomide market from 2021 to 2025

The post Investigation Report on China’s Temozolomide Market 2021-2025 first appeared on CRI Report.

]]>